Astute Medical

Astute is working with Fosun on Chinese trials for the test that it will use to gather data for a submission to the Chinese Food and Drug Administration.

The company has no plans to position NephroCheck for long-term prognosis but said the findings bolster data supporting use of the test in the acute setting.

From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.

NEW YORK (GenomeWeb) – With the recent clearance by the US Food and Drug Administration of its NephroCheck test for acute kidney injury, Astute Medical has achieved a milestone under the terms of its loan agreement with CRG which releases from CRG up to $30 million to support commercialization of

NEW YORK (GenomeWeb) – Astute Medical said this week that it has received US Food and Drug Administration 510(k) clearance for its NephroCheck Test System, a protein biomarker-based test for assessing risk of acute kidney injury.

NEW YORK (GenomeWeb) – Astute Medical said today that it has received US Food and Drug Administration 510(k) clearance for its NephroCheck Test System, a protein biomarker-based test for assessing risk of acute kidney injury.

NEW YORK (GenomeWeb) – Astute Medical said this week that it has entered a strategic collaboration with Ortho-Clinical Diagnostics to expand sales of its NephroCheck test for acute kidney injury.

A paper published last week in PLOS One indicates that Astute Medical's NephroCheck test can help predict development of acute kidney failure in patients after undergoing cardiac surge

Researchers have completed a prospective, multi-center clinical trial validating the performance of Astute Medical's NephroCheck protein biomarker test for acute kidney disease.

Combining metabolomics and proteomics, a consortium of academic and industry researchers has identified a signature that appears useful for predicting death in sepsis patients.

Pages

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.